<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SKLICE- ivermectinÂ lotionÂ </strong><br>Sanofi Pasteur, Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use SKLICE<span class="Sup">â„¢</span> Lotion safely and effectively. Â See full prescribing information for SKLICE Lotion.
			<br><br>SKLICE (ivermectin) Lotion, 0.5%for topical use<br>
			Initial U.S. Approval: Â 1996
		</span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">SKLICE Lotion is a pediculicide indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="132835" conceptname="Pediculosis capitis">head lice</span> <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span> in patients 6 months of age and older. (<a href="#KS0104c5557cd-c4cf-11df-851a-0800200c9a66">1</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>For topical use only.  Not for oral, ophthalmic or intravaginal use. (<a href="#KS0204c5557cd-c4cf-11df-851a-0800200c9a66">2</a>)</li>
<li>Apply SKLICE Lotion to <span class="product-label-link" type="condition" conceptid="4194803" conceptname="Dry hair">dry hair</span> in an amount sufficient (up to 1 tube) to thoroughly coat the hair and scalp. Â (<a href="#KS0204c5557cd-c4cf-11df-851a-0800200c9a66">2</a>)</li>
<li>After 10 minutes, rinse off with water. Â (<a href="#KS0204c5557cd-c4cf-11df-851a-0800200c9a66">2</a>)</li>
<li>For single use.  Discard any unused portion. (<a href="#KS0204c5557cd-c4cf-11df-851a-0800200c9a66">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Lotion: 0.5% (<a href="#KS0304c5557cd-c4cf-11df-851a-0800200c9a66">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. (<a href="#KS0404c5557cd-c4cf-11df-851a-0800200c9a66">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>Accidental ingestion in pediatric patients may occur: Â Administer only under direct adult supervision. Â <a href="#e1-b86c-0800200c9a66-dc51">(5.1)</a>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Â Most common adverse reactions (incidence &lt;1%) are <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="4308080" conceptname="Pityriasis simplex">dandruff</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, and <span class="product-label-link" type="condition" conceptid="4010479" conceptname="Sensation of burning of skin">skin burning sensation</span>. (<a href="#KS0604c5557cd-c4cf-11df-851a-0800200c9a66">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sanofi Pasteur, Inc. at 1-800-835-3592 or FDA at 1-800-FDA-1088 or <span class="Italics Underline">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Safety and effectiveness in pediatric patients below the age of 6 months have not been established. (<a href="#KS0844c5557cd-c4cf-11df-851a-0800200c9a66">8.4</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Indication</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Adjunctive Measures</a></h2>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Ingestion in Pediatric Patients</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h1><a href="#section-7" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5  Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-9" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2  Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14  CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="KS0104c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="e1-b86c-0800200c9a66-dc11"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Indication</h2>
<p class="First">SKLICE<span class="Sup">â„¢</span> Lotion is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="132835" conceptname="Pediculosis capitis">head lice</span> <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span> in patients 6 months of age and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e1-b86c-0800200c9a66-dc12"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Adjunctive Measures</h2>
<p class="First">SKLICE Lotion should be used in the context of an overall lice management program:</p>
<ul>
<li>Wash (in hot water) or dry-clean all recently worn clothing, hats, used bedding and towels.</li>
<li>Wash personal care items such as combs, brushes and hair clips in hot water.</li>
<li>A fine-tooth comb or special nit comb may be used to remove dead lice and nits.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="KS0204c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<p class="First">For topical use only. Â SKLICE Lotion is not for oral, ophthalmic, or intravaginal use.</p>
<p>Apply SKLICE Lotion to <span class="product-label-link" type="condition" conceptid="4194803" conceptname="Dry hair">dry hair</span> in an amount sufficient (up to 1 tube) to thoroughly coat the hair and scalp. Â Leave SKLICE Lotion on the hair and scalp for 10 minutes, and then rinse off with water.</p>
<p>The tube is intended for single use; discard any unused portion.</p>
<p>Avoid contact with eyes.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="KS0304c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Lotion: Â 0.5%; each gram of lotion contains 5 mg of ivermectin. Â SKLICE Lotion is an off-white to tan lotion.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="KS0404c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LD0500"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="e1-b86c-0800200c9a66-dc51"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Ingestion in Pediatric Patients</h2>
<p class="First">In order to prevent ingestion, SKLICE Lotion should only be administered to pediatric patients under the direct supervision of an adult.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="KS0604c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="KS0614c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The data described below reflect exposure to a single 10 minute treatment of SKLICE Lotion in 379 patients, ages 6 months and older, in placebo-controlled trials. Of these subjects, 47 subjects were age 6 months to 4 years, 179 subjects were age 4 to 12 years, 56 subjects were age 12 to 16 years and 97 subjects were age 16 or older. Â Adverse reactions, reported in less than 1% of subjects treated with SKLICE Lotion, include <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="4308080" conceptname="Pityriasis simplex">dandruff</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, and <span class="product-label-link" type="condition" conceptid="4010479" conceptname="Sensation of burning of skin">skin burning sensation</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="KS0804c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-7"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="KS0814c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-7.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First">Pregnancy Category C</p>
<p>There are no adequate and well-controlled studies with SKLICE Lotion in pregnant women. Â SKLICE Lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>No comparisons of animal exposure with human exposure are provided due to the low systemic exposure noted in the clinical pharmacokinetic study <span class="Italics">[see Clinical Pharmacology (<a href="#KS1234c5557cd-c4cf-11df-851a-0800200c9a66">12.3</a>)]</span>.</p>
<p>Human Data</p>
<p>There are published reports of oral ivermectin use during human pregnancy. Â Â In an open label study, 397 women in their second trimester of pregnancy were treated with ivermectin tablets and albendazole at the labeled dose rate for soil-transmitted helminths and compared with a pregnant, non-treated population. Â No differences in pregnancy outcomes were observed between treated and untreated populations.</p>
<p>Animal Data</p>
<p>Systemic embryofetal development studies were conducted in mice, rats and rabbits. Â Oral doses of 0.1, 0.2, 0.4, 0.8, and 1.6 mg/kg/day ivermectin were administered during the period of organogenesis (gestational days 6â€“15) to pregnant female mice. Â Maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> occurred at 0.4 mg/kg/day and above. Â <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">Cleft palate</span> occurred in the fetuses from the 0.4, 0.8, and 1.6 mg/kg/day groups. Â <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">Exencephaly</span> was seen in the fetuses from the 0.8 mg/kg group. Â Oral doses of 2.5, 5, and 10 mg/kg/day ivermectin were administered during the period of organogenesis (gestational days 6â€“17) to pregnant female rats. Â Maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and pre-implantation loss occurred at 10 mg/kg/day. Â <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">Cleft palate</span> and wavy ribs were seen in fetuses from the 10 mg/kg/day group. Â Oral doses of 1.5, 3, and 6 mg/kg/day ivermectin were administered during the period of organogenesis (gestational days 6â€“18) to pregnant female rabbits. Â Maternal toxicity and abortion occurred at 6 mg/kg/day. Â <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">Cleft palate</span> and <span class="product-label-link" type="condition" conceptid="4279382" conceptname="Clubbing">clubbed</span> forepaws occurred in the fetuses from the 3 and 6 mg/kg groups. Â These teratogenic effects were found only at or near doses that were maternally toxic to the pregnant female. Â Therefore, ivermectin does not appear to be selectively fetotoxic to the developing fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="KS0834c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Following oral administration, ivermectin is excreted in human milk in low concentrations. Â This has not been evaluated following topical administration. Caution should be exercised when SKLICE Lotion is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="KS0844c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-7.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">The safety and effectiveness of SKLICE Lotion have been established for pediatric patients 6 months of age and older <span class="Italics">[see Clinical Pharmacology (<a href="#KS1234c5557cd-c4cf-11df-851a-0800200c9a66">12.3</a>) and Clinical Studies (<a href="#KS1404c5557cd-c4cf-11df-851a-0800200c9a66">14</a>)]</span>.</p>
<p>The safety of SKLICE Lotion has not been established in pediatric patients below the age of 6 months. Â SKLICE Lotion is not recommended in pediatric patients under 6 months of age because of the potential increased systemic absorption due to a high ratio of skin surface area to body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> and the potential for an immature skin barrier and risk of ivermectin toxicity.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="KS0854c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-7.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">Clinical studies of SKLICE Lotion did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="KS1004c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-8"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">In accidental or significant exposure to unknown quantities of veterinary formulations of ivermectin in humans, either by ingestion, inhalation, injection, or exposure to body surfaces, the following adverse effects have been reported most frequently: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Other adverse effects that have been reported include: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>.</p>
<p>In case of accidental <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, supportive therapy, if indicated, should include parenteral fluids and electrolytes, respiratory support (oxygen and mechanical ventilation if necessary) and pressor agents if clinically significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is present. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and/or gastric lavage as soon as possible, followed by purgatives and other routine anti-poison measures, may be indicated if needed to prevent absorption of ingested material.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="KS1104c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-9"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">SKLICE (ivermectin) Lotion, for topical administration, is an off-white/tan lotion containing 0.5% ivermectin.</p>
<p>Ivermectin, the active ingredient, is a pediculicide, derived from the fermentation of a soil dwelling actinomycete, <span class="Italics">Streptomyces avermitilis.</span></p>
<p>Ivermectin is a mixture containing at least 90% 5-<span class="Italics">O</span>-demethyl-22,23-dihydroavermectin A<span class="Sub">1a</span> and less than 10% 5-<span class="Italics">O</span>-demethyl-25-de(1-methylpropyl)-22,23-dihydro25-(1-methylethyl) avermectin A<span class="Sub">1a</span>, generally referred to as 22,23-dihydroavermectin B<span class="Sub">1a</span> and B<span class="Sub">1b</span>, or H<span class="Sub">2</span>B<span class="Sub">1a</span> and H<span class="Sub">2</span>B<span class="Sub">1b</span>, respectively. The respective empirical formulas are C<span class="Sub">48</span>H<span class="Sub">74</span>O<span class="Sub">14</span> and C<span class="Sub">47</span>H<span class="Sub">72</span>O<span class="Sub">14</span>, with molecular weights of 875.10 and 861.07, respectively. The structural formulas are:</p>
<div class="Figure"><img alt="Structural Formulas of Ivermectin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c5557cd-c4cf-11df-851a-0800200c9a66&amp;name=sklice-figure-1.jpg"></div>
<p>Component H<span class="Sub">2</span>B<span class="Sub">1a</span>: R = CH<span class="Sub">2</span>CH<span class="Sub">3</span>  Component H<span class="Sub">2</span>B<span class="Sub">1b</span>: R = CH<span class="Sub">3</span></p>
<p>SKLICE Lotion contains the following inactive ingredients: water, olive oil, oleyl alcohol, Crodalan AWS, lanolin alcohol, cyclomethicone, shea butter, sodium citrate, sorbitan tristearate, methylparaben, propylparaben, and citric acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="KS1204c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-10"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="KS1214c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-10.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Ivermectin, a member of the avermectin class, causes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of parasites, primarily through binding selectively and with high affinity to glutamate-gated chloride channels, which occur in invertebrate nerve and muscle cells. Â This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the parasite. Â Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA). Â The selective activity of compounds of this class is attributable to the fact that some mammals do not have glutamate-gated chloride channels, the avermectins have a low affinity for mammalian ligand-gated chloride channels, and ivermectin does not readily cross the blood-brain barrier in humans.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="e1-b86c-0800200c9a66-dc123"></a><a name="section-10.2"></a><p></p>
<h2>12.2  Pharmacodynamics</h2>
<p class="First">The pharmacodynamics of SKLICE Lotion are unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="KS1234c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-10.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">The absorption of ivermectin from SKLICE Lotion was evaluated in a clinical study in subjects aged from 6 months to 3 years. Â This study evaluated pharmacokinetics in 20 lice infested subjects, and 13 of these subjects weighed 15 kg or less (overall weight range 8.5-23.9 kg). Â All enrolled subjects received a single treatment with SKLICE Lotion. Â The systemic ivermectin exposure was evaluated using an assay with a lower limit of quantitation of 0.05 ng/mL. The mean (Â± standard deviation) plasma maximum concentration (C<span class="Sub">max</span>) and area under the concentration-time curve from 0 to time of last measurable concentration (AUC<span class="Sub">0-tlast</span>) were 0.24 Â± 0.23 ng/mL and Â 6.7Â  Â± 11.2hrâ€¢ng/mL, respectively. These levels are much lower than those observed following oral administration of 165 mcg/kg dose of ivermectin.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="KS1304c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-11"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="KS1314c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-11.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the carcinogenic potential of SKLICE Lotion or ivermectin.</p>
<p>Ivermectin was not genotoxic <span class="Italics">in vitro</span> in the Ames test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, or the unscheduled DNA synthesis assay in human fibroblasts.</p>
<p>Ivermectin had no adverse effects on fertility in rats at repeated oral doses of up to 3.6 mg/kg/day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="KS1404c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-12"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First">Two identical multi-center, randomized, double-blind, vehicle-controlled studies were conducted in subjects 6 months of age and older with <span class="product-label-link" type="condition" conceptid="132835" conceptname="Pediculosis capitis">head lice</span> <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>. All subjects received a single application of either SKLICE Lotion or vehicle control with instructions not to use a nit comb. For the evaluation of efficacy, the youngest subject from each household was considered to be the index subject of the household (N=289). Other enrolled infested household members received the same treatment as the youngest subject and were evaluated for all safety parameters <span class="Italics">[see Adverse Reactions (<a href="#KS0614c5557cd-c4cf-11df-851a-0800200c9a66">6.1</a>)]</span>.</p>
<p>The primary efficacy was assessed as the proportion of index subjects who were free of live lice at day 2 and through day 8 to the final evaluation 14 (+2) days following a single application. Subjects with live lice present at any time up to the final evaluation were considered treatment failures. Table 1 contains the proportion of subjects who were free of live lice in each of the two trials.</p>
<table width="600">
<caption><span>Table 1: Proportion of Subjects Free of Live Lice 14 Days After Treatment</span></caption>
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"><span class="Bold">Study</span></td>
<td align="center"><span class="Bold">Vehicle<br>
										% (n/N)</span></td>
<td align="center"><span class="Bold">SKLICE Lotion<br>
										% (n/N)</span></td>
</tr>
<tr>
<td>Study 1</td>
<td align="center">16.2% (12/74)</td>
<td align="center">76.1% (54/71)</td>
</tr>
<tr class="Last">
<td>Study 2</td>
<td align="center">18.9% (14/74)</td>
<td align="center">71.4% (50/70)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="KS1604c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-13"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">SKLICE Lotion, 0.5% is supplied in a 4 oz (117g) laminate tube (NDC 49281-183-71).</p>
<p>Store at room temperature 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP controlled room temperature]. Â Do not freeze.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="KS1704c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-14"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">â€œSee FDA-approved patient labeling (<a href="#KS1804c5557cd-c4cf-11df-851a-0800200c9a66">Patient Information</a>)".</p>
<p>Inform the patient and caregiver of the following instructions:</p>
<ul>
<li>Apply SKLICE Lotion to <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry scalp</span> and <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry scalp</span> hair.</li>
<li>Avoid contact with eyes.</li>
<li>Do not swallow SKLICE Lotion.</li>
<li>Keep out of reach of children. Â Use on children should be under the direct supervision of an adult.</li>
<li>For single use only; do not retreat.</li>
<li>Discard tube after use.</li>
<li>Wash hands after applying SKLICE Lotion.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="KS1804c5557cd-c4cf-11df-851a-0800200c9a66"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">SKLICEâ„¢ (sklice) (ivermectin) Lotion, 0.5%</span></p>
<p><span class="Bold">Important: Â For use on scalp hair and scalp only. Â Do not use SKLICE Lotion in your eyes, mouth or vagina.</span></p>
<p>Read the Patient Information that comes with SKLICE Lotion.  Â This leaflet does not take the place of talking to your healthcare provider about your medical condition or treatment.</p>
<p><span class="Bold">What is SKLICE Lotion?</span><br>
							SKLICE Lotion is a prescription medicine for topical use on the hair and scalp only. SKLICE Lotion is used to treat <span class="product-label-link" type="condition" conceptid="132835" conceptname="Pediculosis capitis">head lice</span> in people 6 months of age and older.
							<br><br>It is not known if SKLICE Lotion is safe and effective for children under 6 months of age.<br></p>
<p><span class="Bold">What should I tell my healthcare provider before I use SKLICE Lotion?</span><br>
							Before using SKLICE Lotion, tell your healthcare provider if you or your child:</p>
<ul>
<li>have any skin conditions or sensitivities,</li>
<li>have any other medical conditions,</li>
<li>are pregnant or plan to become pregnant. It is not known if SKLICE Lotion can harm your unborn baby, and</li>
<li>are breastfeeding or plan to breastfeed. It is not known if SKLICE Lotion passes into your breast milk. Talk to your healthcare provider if you are breastfeeding.</li>
</ul>
<p><span class="Bold">How should I use SKLICE Lotion?</span></p>
<ul>
<li>Use SKLICE Lotion exactly as prescribed. Your healthcare provider will prescribe the treatment that is right for you. Do not change your treatment unless you talk to your healthcare provider.</li>
<li>Use SKLICE Lotion when your hair is dry.</li>
<li>It is important to use enough SKLICE Lotion to completely coat all of your hair and scalp. Leave SKLICE Lotion on your hair and scalp for a full 10 minutes. <span class="Bold">See the detailed <a href="#KS1814c5557cd-c4cf-11df-851a-0800200c9a66">â€œPatient Instructions for Useâ€?</a> at the end of this leaflet.</span>
</li>
<li>You need to completely cover all the scalp and hair with lotion. Make sure that you and anyone who helps you apply SKLICE Lotion reads and understands this leaflet and the Patient Instructions for Use.</li>
<li>Children will need an adult to apply SKLICE Lotion for them.</li>
<li>Do not swallow SKLICE Lotion. If swallowed, call your healthcare provider or go to the nearest emergency room right away.</li>
<li>Do not get SKLICE Lotion into your eyes. If SKLICE Lotion gets in your eye, gently flush with water.</li>
<li>Wash your hands after applying SKLICE Lotion.</li>
</ul>
<p>When you complete your dose of SKLICE Lotion, do not use SKLICE Lotion again without talking to your healthcare provider first.</p>
<p><span class="Bold">What are the possible side effects of SKLICE Lotion?</span></p>
<br><p><span class="Bold">The most common side effects of SKLICE Lotion include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span> or soreness</li>
<li><span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span></li>
<li><span class="product-label-link" type="condition" conceptid="4308080" conceptname="Pityriasis simplex">dandruff</span></li>
<li><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span></li>
<li><span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> of the skin</li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.<br><br>These are not all the possible side effects of SKLICE Lotion. For more information, ask your healthcare provider or pharmacist.<br><br>Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store SKLICE Lotion?</span></p>
<ul>
<li>Store SKLICE Lotion at room temperature between 68Â° to 77Â°F (20Â° to 25Â°C).</li>
<li>Do not freeze SKLICE Lotion.</li>
<li>Safely throw away any unused SKLICE Lotion.</li>
</ul>
<p><span class="Bold">Keep SKLICE Lotion and all medicines out of reach of children.</span></p>
<br><p><span class="Bold">What are the ingredients in SKLICE Lotion?</span><br>
							Active ingredient: ivermectin<br>
							Inactive ingredients:water, olive oil, oleyl alcohol, Crodalan AWS, lanolin alcohol, cyclomethicone, shea butter, sodium citrate, sorbitan tristearate, methylparaben, propylparaben, and citric acid</p>
<p><span class="Bold">General information about SKLICE Lotion</span><br>
							Medicines are sometimes prescribed for purposes other than those listed in a  Patient Information leaflet. Do not use SKLICE Lotion for a condition for which it was not prescribed. Do not give SKLICE Lotion to other people, even if they have the same symptoms you have. It may harm them. This Patient Information leaflet summarizes the most important information about SKLICE Lotion. If you would like more information, talk to your healthcare provider.  You can also ask your healthcare provider or pharmacist for information about SKLICE Lotion that is written for health professionals.</p>
<p><a name="KS1814c5557cd-c4cf-11df-851a-0800200c9a66"></a><span class="Bold">Patient Instructions for Use</span><br><br>Before you use SKLICE Lotion, it is important that you read the Patient Information and these Patient Instructions for Use.  Be sure that you read, understand, and follow these Patient Instructions for Use so that you use SKLICE Lotion  the right way. Â Ask your healthcare provider or pharmacist if you have questions about the right way to use SKLICE Lotion.</p>
<ul><li>Your hair and scalp must be <span class="Underline">dry</span> before applying SKLICE Lotion.</li></ul>
<p><span class="Bold">Â Â Figure A</span><br><img alt="Figure A: Use the top of cap to break the tamper seal on the tube" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c5557cd-c4cf-11df-851a-0800200c9a66&amp;name=sklice-figure-2.jpg"><br>
									â€¢ Use the top of cap to break the tamper seal on the tube (see Figure A).<br></p>
<p><span class="Bold">Â Figure BÂ Â Â Figure CÂ Â Figure D</span><br><img alt="Figure B: Apply SKLICE Lotion directly to <span class="product-label-link" type="condition" conceptid="4194803" conceptname="Dry hair">dry hair</span> and scalp
								Figure C: Completely cover your scalp and hair closest to the scalp first, and then apply outwards towards the ends of your hair
								Figure D: Rub SKLICE Lotion throughout your hair" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c5557cd-c4cf-11df-851a-0800200c9a66&amp;name=sklice-figure-3.jpg"></p>
<ul>
<li>Apply SKLICE Lotion directly to <span class="Bold"><span class="product-label-link" type="condition" conceptid="4194803" conceptname="Dry hair">dry hair</span></span> and <span class="Bold">scalp</span> (see Figure B).</li>
<li>Completely cover your scalp and hair closest to the scalp first, and then apply outwards towards the ends of your hair (see Figure C).</li>
<li>Rub SKLICE Lotion throughout hair (see Figure D).</li>
<li>It is important to completely cover your entire head so that all lice and eggs are exposed to the lotion. Be sure that each hair is coated from the scalp to the tip. </li>
<li>Use up to 1 entire tube (4 oz) to completely cover hair and scalp.</li>
</ul>
<p><span class="Bold">Â Figure EÂ Â Â Figure F</span></p>
<p><img alt="Figure E: Allow SKLICE Lotion to stay on your hair and scalp for 10 minutes after it has been applied. Use a timer or clock. Start timing after you have completely covered your hair and scalp with SKLICE Lotion
								Figure F: After 10 minutes, completely rinse SKLICE Lotion from your hair and scalp using only water" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c5557cd-c4cf-11df-851a-0800200c9a66&amp;name=sklice-figure-4.jpg"></p>
<ul>
<li>Allow SKLICE Lotion to stay on your hair and scalp for 10 minutes after it has been applied. Use a timer or clock. Start timing after you have completely covered your hair and scalp with SKLICE Lotion (see Figure E).</li>
<li>After 10 minutes, completely rinse SKLICE Lotion from your hair and scalp using only water (see Figure F).</li>
<li>You or anyone who helps you apply SKLICE Lotion should wash their hands after application.</li>
<li>Do not use SKLICE Lotion again without talking to your healthcare provider first.</li>
</ul>
<p><span class="Bold">How do I stop the spread of lice?</span><br>
							To help prevent the spread of lice from one person to another, here are some steps you can take:</p>
<ul>
<li>Avoid direct head-to-head contact with anyone known to have live, crawling lice.</li>
<li>Do not share combs, brushes, hats, scarves, bandannas, ribbons, barrettes, hair bands, towels, helmets, or other hair-related personal items with anyone else, whether they have lice or not.</li>
<li>Avoid sleepovers and slumber parties during lice outbreaks. Lice can live in bedding, pillows, and carpets that have recently been used by someone with lice.</li>
<li>After finishing treatment with lice medicine, check everyone in your family for lice after one week. Be sure to talk to your healthcare provider about treatments for those who have lice.</li>
<li>Machine wash any bedding and clothing used by anyone having lice. Machine wash at <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperatures</span> (150Â°F) and tumble in a hot dryer for 20 minutes.</li>
</ul>
<p><span class="Bold">This Patient Information has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Distributed by:<br>
							Sanofi Pasteur Inc.<br>
							Swiftwater, PA 18370</p>
<p>Manufactured by:<br>
							DPT Laboratories LTD<br>
							San Antonio, TX 78215<br><br>
							129685<br></p>
<p>U.S. Patent No. 6,103,248 and other patents pending.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="e1-b86c-0800200c9a66-dc5"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - Sklice Tube Label</span></p>
<p><img alt="Sklice Tube Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c5557cd-c4cf-11df-851a-0800200c9a66&amp;name=sklice-figure-5.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="e1-b86c-0800200c9a66-dc6"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - Sklice Tube Carton</span></p>
<p><img alt="Sklice Tube Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c5557cd-c4cf-11df-851a-0800200c9a66&amp;name=sklice-figure-6.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SKLICEÂ 		
					</strong><br><span class="contentTableReg">ivermectin lotion</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49281-183</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IVERMECTIN</strong> (IVERMECTIN) </td>
<td class="formItem">IVERMECTIN</td>
<td class="formItem">0.585Â g Â inÂ 117Â g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-183-71</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">117 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202736</td>
<td class="formItem">07/09/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Sanofi Pasteur, Inc
							(086723285)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">DPT Laboratories LTD</td>
<td class="formItem"></td>
<td class="formItem">832224690</td>
<td class="formItem">MANUFACTURE(49281-183), ANALYSIS(49281-183), LABEL(49281-183)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hovione Pharmascience Limited</td>
<td class="formItem"></td>
<td class="formItem">854974342</td>
<td class="formItem">API MANUFACTURE(49281-183)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d78e1180-5714-11e1-b7ee-0002a5d5c51b</div>
<div>Set id: 4c5557cd-c4cf-11df-851a-0800200c9a66</div>
<div>Version: 3</div>
<div>Effective Time: 20120217</div>
</div>
</div>Â <div class="DistributorName">Sanofi Pasteur, Inc</div></p>
</body></html>
